Global Zika Virus Testing Market Overview

The global Zika virus testing market was valued at USD 209.5 million in 2023 and is projected to reach USD 341.6 million by 2030, growing at a compound annual growth rate (CAGR) of 7.3% between 2024 and 2030. This growth is primarily driven by the increasing incidence of Zika virus infections, especially in endemic areas, which continues to drive the demand for diagnostic testing.

Technological advancements in testing methods and heightened global awareness following previous outbreaks—particularly due to Zika’s link with severe birth defects—are further contributing to market expansion. The COVID-19 pandemic has also indirectly supported market growth by increasing global attention on infectious disease diagnostics, including those for the Zika virus.

Zika virus outbreaks have been observed across multiple regions, including North America, Asia Pacific, and Europe. The virus is known to spread through mosquito bites and sexual transmission. Individuals with weakened immune systems and newborns are at greater risk of severe symptoms. Of particular concern is the risk to pregnant women, as Zika virus infection during pregnancy is associated with miscarriage and congenital conditions such as microcephaly. This has heightened awareness of the importance of timely and accurate Zika virus testing.

Order a free sample PDF of the Zika Virus Testing Market Intelligence Study, published by Grand View Research

According to the World Health Organization (WHO), Zika virus infection remains endemic in parts of Africa and Southeast Asia, with recurring outbreaks reported in Asia-Pacific regions (especially India) and South America. The virus continues to pose a threat, with ongoing transmission in several countries.

Additionally, the healthcare industry has faced numerous viral outbreaks in the current decade—including SARS, Chikungunya, Swine Flu, and Zika virus—creating sustained demand for improved diagnostic technologies. Government initiatives focused on developing novel, effective tests and spreading public awareness of Zika-related risks are playing a key role in advancing the market. The convergence of rising infection rates and technological innovation is expected to support consistent market growth throughout the forecast period.

Key Market Trends & Insights

• North America led the global Zika virus testing market with a 41.8% revenue share in 2023, driven by high awareness, advanced healthcare infrastructure, and government support.
• Within North America, the U.S. dominated with a commanding 93.8% share of the regional market in 2023, due to robust diagnostic capabilities and public health initiatives.
• Based on test type, the serological test segment accounted for the largest revenue share of 51.1% in 2023. These tests are widely used due to their ability to detect antibodies and offer cost-effective, scalable solutions for population-wide screening.
• In terms of end use, the clinical laboratories segment led the market with a 47.4% revenue share in 2023, reflecting the central role of professional lab testing in accurate diagnosis and public health surveillance.

Market Size & Forecast

• Market Size (2023): USD 209.5 Million
• Projected Market Size (2030): USD 341.6 Million
• CAGR (2024–2030): 7.3%
• Leading Region (2023): North America

Key Zika Virus Testing Company Insights

Several leading companies are innovating and expanding their capabilities to enhance their competitive position in the market:

• Abbott Laboratories has developed the RealTime ZIKA test, which received FDA Emergency Use Authorization. This molecular diagnostic detects Zika virus RNA from various sample types, delivering fast and reliable results.
• DiaSorin S.p.A. specializes in in vitro diagnostic solutions and offers Zika testing kits based on Enzyme-Linked Immunosorbent Assays (ELISA) and Chemiluminescence (CLIA) technologies, designed for high-precision diagnostic investigations.

Key Zika Virus Testing Companies

These major players collectively shape market dynamics and innovation trends:

• Abbott
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Quest Diagnostics Incorporated
• Siemens Healthineers AG
• Chembio Diagnostic Systems, Inc.
• SD Biosensors, Inc.
• Biocan Diagnostics
• ARUP Laboratories
• Viatris Inc.

Conclusion

The global Zika virus testing market is positioned for steady growth over the forecast period, supported by increasing disease prevalence, advancements in diagnostic technologies, and governmental initiatives aimed at controlling outbreaks and promoting early detection. Regions experiencing ongoing transmission, especially in Africa, Southeast Asia, and parts of Latin America, continue to drive demand for efficient testing solutions.

The market also benefits from the broader public health focus on preventing congenital birth defects linked to Zika virus infection, especially among pregnant women. As diagnostic tools become more accessible, scalable, and accurate, the Zika virus testing market is expected to remain a critical component of global infectious disease management and pandemic preparedness efforts.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.